





DEVELOPMENTAL NEUROPATHOLOGY

SECOND EDITION

SERIES EDITORS
FRANÇOISE GRAY | KATY KEOHANE

EDITED BY
HOMA ADLE-BIASSETTE
BRIAN N. HARDING
JEFFREY A. GOLDEN



WILEY Blackwell

Developmental Neuropathology

Developmental Neuropathology

SECOND EDITION

EDITED BY

HOMA ADLE-BIASSETTE

Université Paris Diderot, Paris

BRIAN N. HARDING

Children's Hospital of Philadelphia, Philadelphia

JEFFREY A. GOLDEN

Ramzi S. Cotran Professor of Pathology, Boston

SERIES EDITORS

FRANÇOISE GRAY

Université Denis Diderot Paris 7, France

CATHERINE (KATY) KEOHANE

University College Cork, Ireland

WILEY Blackwell



This first published 2018
© 2018 John Wiley & Sons Ltd

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

The right of Homa Adle-Biassette, Brian N. Harding and Jeffrey A. Golden to be identified as the authors of the editorial material in this work has been asserted in accordance with law.

Registered Office(s) John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA
John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Office 9600 Garsington Road, Oxford, OX4 2DQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data

Names: Adle-Biassette, Homa, editor. | Harding, Brian (Brian N.), editor. | Golden, Jeffrey A., 1961– editor.
Title: Developmental neuropathology / [edited] by Homa Adle-Biassette, Brian Harding, Jeffrey A. Golden.
Description: Second edition. | Hoboken, NJ : Wiley, 2018. | Includes bibliographical references and index. |
Identifiers: LCCN 2017050347 (print) | LCCN 2017051636 (ebook) | ISBN 9781119013099 (pdf) | ISBN
9781119013105 (epub) | ISBN 9781119013082 (cloth)
Subjects: | MESH: Central Nervous System Diseases–genetics | Central Nervous System Diseases–pathology |
Genetic Diseases, Inborn–pathology | Nervous System Malformations–pathology
Classification: LCC RC347 (ebook) | LCC RC347 (print) | NLM WL 301 | DDC 616.8/047–dc23
LC record available at <https://lccn.loc.gov/2017050347>

Cover design by: Wiley

Cover images: Main image courtesy of Brian Harding

Smaller images from top to bottom:

1st one courtesy of Brian Harding; 2nd one courtesy of Jeff Golden;

3rd one courtesy of Pr. Hans Goebel; 4th one courtesy of Pr. Annie Laquerrière;

5th one courtesy of Jeff Golden

Set in 9.5/12pt Minion by Aptara Inc., New Delhi, India

10 9 8 7 6 5 4 3 2 1

Contents

- List of Contributors, vii
- Introduction, xiii
- 1 Central Nervous System Manifestations of Chromosomal Change, 1
Joseph R. Siebert
- 2 Neural Tube Defects, 13
Andrew J. Copp and Brian N. Harding
- 3 Midline Patterning Defects, 29
Edwin S. Monuki and Jeffrey A. Golden
- 4 Microcephaly, 41
Sandrine Passemard, Annie Laquerrière, Nathalie Journiac, and Pierre Gressens
- 5 Hemimegalencephaly and Dysplastic Megalencephaly, 55
Ghayda Mirzaa, Achira Roy, William B. Dobyns, Kathleen Millen, and Robert F. Hevner
- 6 Lissencephaly, Type I, 63
Jeffrey A. Golden
- 7 Lissencephaly, Type II (Cobblestone Lissencephaly), 75
Jeffrey A. Golden
- 8 Polymicrogyria, 85
Jeffrey A. Golden
- 9 Cerebral Heterotopia, 91
Edwin S. Monuki and Keith L. Ligon
- 10 Hippocampal Sclerosis, Granule Cell Dispersion, and Cortical Dysplasia, 101
Maria Thom
- 11 Tuberous Sclerosis Complex, 117
Shino D. Magaki and Harry V. Vinters
- 12 Chiari Malformations, 133
Homa Adle-Biassette and Jeffrey A. Golden
- 13 Dandy–Walker Malformation, Mega Cisterna Magna, and Blake’s Pouch Cyst, 141
Robert F. Hevner, Kathleen Millen, and William B. Dobyns
- 14 Joubert Syndrome, 151
Robert F. Hevner, William B. Dobyns, and Enza Maria Valente
- 15 Cerebellar Heterotopia and Dysplasia, 159
Marie Rivera-Zengotita and Anthony T. Yachnis
- 16 Brainstem Malformations, 167
Brian N. Harding
- 17 Spinal Cord Lesions, 179
Annie Laquerrière and Florent Marguet
- 18 Hydrocephalus, 187
Homa Adle-Biassette
- 19 Antenatal Disruptive Lesions, 199
Brian N. Harding
- 20 Hemorrhagic Lesions, 203
Marc R. Del Bigio
- 21 White Matter Lesions in the Perinatal Period, 213
Robin L. Haynes and Rebecca D. Folkerth
- 22 Gray Matter Lesions, 229
Marc R. Del Bigio
- 23 Pediatric Head Injury, 241
Colin Smith, Thomas S. Jacques, and R. Ross Reichard
- 24 Pediatric Vascular Malformations, 251
Shino D. Magaki, Randy Tashjian, and Harry V. Vinters

Contents

- 25 Sudden Infant Death Syndrome, 269
*Hannah C. Kinney, Marco M. Hefti,
Richard D. Goldstein, and Robin L. Haynes*
- 26 Kernicterus, 281
Mariarita Santi and Lucy B. Rorke
- 27 Lesions Induced by Toxins, 285
*Mariarita Santi, Lucy B. Rorke,
and Catherine Keohane*
- 28 Disorders of Carbohydrate Metabolism, 293
*Josefine Radke, Carsten G. Bönnemann,
Werner Stenzel, and Hans-H. Goebel*
- 29 Sphingolipidoses and Related Disorders, 313
*Annie Laquerrière, Soumeya Bekri, Kinoko Suzuki,
and Brian N. Harding*
- 30 The Neuronal Ceroid Lipofuscinoses, 369
*Josefine Radke, Krystina E. Wisniewski,
Werner Stenzel, and Hans-H. Goebel*
- 31 Peroxisomal Disorders, 381
Phyllis L. Faust
- 32 Mitochondrial Disorders, 393
Anders Oldfors and Brian N. Harding
- 33 Disorders of Amino Acid Metabolism and Canavan
Disease, 403
Dimitri P. Agamanolis
- 34 Pelizaeus–Merzbacher Disease, 417
Brian N. Harding
- 35 Cockayne Syndrome, 427
Karen M. Weidenheim and P. J. Brooks
- 36 Vanishing White Matter Disease, 437
*Marianna Bugiani, James M. Powers,
and Marjo S. van der Knaap*
- 37 Alexander Disease, 447
James E. Goldman and Mel B. Feany
- 38 Neuroaxonal Dystrophy/Neurodegeneration
with Brain Iron Accumulation, 455
*Abi Li, Sarah Wiethoff, Charles Arber, Henry Houlden,
Tamas Revesz, and Janice L. Holton*
- 39 Spinal Muscular Atrophy, 469
Brian N. Harding
- 40 Autism Spectrum Disorders, 477
Matthew P. Anderson
- 41 Intrauterine Infections, 497
Catherine Keohane and Homa Adle-Biassette
- 42 Perinatal and Postnatal Infections, 511
Catherine Keohane
- 43 Rasmussen Encephalitis, 531
*Harry V. Vinters, Shino D. Magaki,
and Geoffrey C. Owens*
- Index, 537

List of Contributors

Lucy B. Rorke

Department of Pathology and Laboratory Medicine
Children's Hospital of Philadelphia
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
USA

Homa Adle-Biassette

Department of Pathology, APHP, Lariboisière Hospital,
Université Paris Diderot
Paris
France

Dimitri P. Agamanolis

Department of Pathology
Akron Childrens Hospital
Akron, OH
USA;

Department of Pathology
Northeast Ohio Medical Universities (NEOMED)
Rootstown, OH
USA

Matthew P. Anderson

Department of Pathology
Division of Neuropathology
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston, MA
USA

Charles Arber

Department of Molecular Neuroscience
UCL Institute of Neurology
University College London
London
UK

Soumeya Bekri

Department of Metabolic Biochemistry
University Hospital
Rouen
France

Carsten G. Bönnemann

Neuromuscular and Neurogenetic Disorders of Childhood
Section
National Institute of Neurological Disorders and Stroke/NIH
Porter Neuroscience Research Center
Bethesda, MD
USA

P. J. Brooks

Office of Rare Diseases Research and Division of Clinical
Innovation
National Center for Advancing Translational Sciences
National Institutes of Health and Laboratory of Neurogenetics
National Institute of Alcohol Abuse and Alcoholism
National Institutes of Health
Bethesda, MD
USA

Marianna Bugiani

Departments of Child Neurology and Pathology
VU University Medical Center, Amsterdam
The Netherlands

Andrew J. Copp

Newlife Birth Defects Centre
Institute of Child Health
University College London
London
UK

List of Contributors

Marc R. Del Bigio

Department of Pathology
University of Manitoba
Winnipeg
Canada;

Diagnostic Services Manitoba
Children's Hospital Research Institute of Manitoba
Winnipeg
Canada

William B. Dobyns

Department of Pediatrics
University of Washington
Seattle, WA
USA;

Center for Integrative Brain Research
Seattle Children's Research Institute
Seattle, WA
USA

Phyllis L. Faust

Columbia University Department of Pathology and Cell
Biology
New York, NY
USA

Mel B. Feany

Department of Pathology
Brigham and Women's Hospital
Harvard Medical School
Boston, MA
USA

Rebecca D. Folkerth

New York City Office of the Chief Medical Examiner
New York University School of Medicine
New York, NY
USA

Hans-H. Goebel

Department of Neuropathology
Charité Universitätsmedizin Berlin
Berlin
Germany

Jeffrey A. Golden

Department of Pathology
Brigham and Women's Hospital
Harvard Medical School
Boston, MA
USA

James E. Goldman

Department of Pathology and Cell Biology
Columbia University
New York, NY
USA

Richard D. Goldstein

Department of General Pediatrics
Children's Hospital Boston
Boston, MA
USA;

Harvard Medical School
Boston, MA
USA

Pierre Gressens

Paris Diderot University
Paris
France;

Inserm U1141
Robert Debré Hospital
Paris
France;

Center for Developing Brain
King's College, St. Thomas' Campus
London
UK

Brian N. Harding

Department of Pathology and Laboratory Medicine
Children's Hospital of Philadelphia
Philadelphia, PA
USA

Robin L. Haynes

Department of Pathology
Boston Children's Hospital
Boston, MA
USA

Marco M. Hefti

Department of Pathology
Mount Sinai Medical Center
New York, NY
USA

Robert F. Hevner

Department of Neurological Surgery
University of Washington
Seattle, WA
USA;

Center for Integrative Brain Research
Seattle Children's Research Institute
Seattle, WA
USA

Janice L. Holton

Queen Square Brain Bank
Reta Lila Weston Institute of Neurological Studies
UCL Institute of Neurology
University College London
London
UK

Henry Houlden

Department of Molecular Neuroscience
UCL Institute of Neurology
University College London
London
UK

Thomas S. Jacques

UCL Institute of Child Health and Great Ormond Street
Hospital
Great Ormond Street Hospital for Children NHS Foundation
Trust
London
UK

Nathalie Journiac

Inserm U1141
Robert Debré Hospital
Paris
France

Catherine Keohane

Department of Pathology and School of Medicine
University College Cork
Ireland

Hannah C. Kinney

Department of Pathology
Boston Children's Hospital
Boston, MA
USA;

Harvard Medical School
Boston, MA
USA

Annie Laquerrière

Department of Pathology
Pavillon Jacques Delarue
Rouen University Hospital
Rouen
France;

Region-Inserm Team NeoVasc ERI28
Laboratory of Microvascular Endothelium and Neonatal Brain
lesions
Institute of Research Innovation in Biomedecine
Normandy University Rouen
Rouen
France

Abi Li

Queen Square Brain Bank
Reta Lila Weston Institute of Neurological Studies
UCL Institute of Neurology
University College London
London
UK

Keith L. Ligon

Division of Neuropathology
Department of Pathology
Brigham and Women's Hospital
Boston, MA
USA

Shino D. Magaki

Section of Neuropathology
Department of Pathology and Laboratory Medicine
David Geffen School of Medicine
University of California
Los Angeles, CA
USA

Florent Marguet

Department of Pathology
Rouen University Hospital
Rouen
France

Kathleen Millen

Center for Integrative Brain Research
Seattle Children's Research Institute
Seattle, WA
USA

Ghayda Mirzaa

Department of Pediatrics
University of Washington
Seattle, WA
USA;

Center for Integrative Brain Research
Seattle Children's Research Institute
Seattle, WA
USA

List of Contributors

Edwin S. Monuki

Department of Pathology and Laboratory Medicine
UC Irvine School of Medicine
Irvine, CA
USA

Anders Oldfors

Department of Pathology
Sahlgrenska University Hospital
Gothenburg
Sweden

Geoffrey C. Owens

Department of Neurosurgery
David Geffen School of Medicine and Ronald Reagan UCLA
Medical Center
University of California
Los Angeles, CA
USA

Sandrine Passemard

Department of Genetics
Robert Debré Hospital
Paris
France;

Paris Diderot University
Paris
France;

Inserm U1141
Robert Debré Hospital
Paris
France

James M. Powers

Department of Pathology and Laboratory Medicine
University Rochester Medical Center
Rochester, NY
USA

Josefine Radke

Department of Neuropathology
Charité Universitätsmedizin Berlin
Berlin
Germany

R. Ross Reichard

Mayo Clinic
Rochester, MN
USA

Tamas Revesz

Queen Square Brain Bank
Reta Lila Weston Institute of Neurological Studies
UCL Institute of Neurology
University College London
London
UK

Marie Rivera-Zengotita

Department of Pathology, Immunology, and Laboratory
Medicine
University of Florida College of Medicine
Gainesville, FL
USA

Achira Roy

Center for Integrative Brain Research
Seattle Children's Research Institute
Seattle, WA
USA

Mariarita Santi

Department of Pathology and Laboratory Medicine
Children's Hospital of Philadelphia
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA
USA

Joseph R. Siebert

Department of Laboratories
Seattle Children's Hospital
Departments of Pathology and Pediatrics
University of Washington
Seattle, WA
USA

Colin Smith

Academic Department of Neuropathology
Centre for Clinical Brain Sciences
University of Edinburgh
Edinburgh
UK

Werner Stenzel

Department of Neuropathology
Charité Universitätsmedizin Berlin
Berlin
Germany

Kinoko Suzuki

Department of Pathology and Laboratory Medicine
University of North Carolina
Chapel Hill, NC
USA

Randy Tashjian

Section of Neuropathology
Department of Pathology and Laboratory Medicine
David Geffen School of Medicine
University of California
Los Angeles, CA
USA

Maria Thom

Departments of Neuropathology and Clinical and
Experimental Epilepsy
UCL Institute of Neurology
London
UK

Enza Maria Valente

Section of Neurosciences
Department of Medicine and Surgery
University of Salerno
Fisciano
Italy

Marjo S. van den Knaap

Department of Child Neurology
VU University Medical Center
Amsterdam
The Netherlands

Harry V. Vinters

Section of Neuropathology
Department of Pathology and Laboratory Medicine
David Geffen School of Medicine
University of California
Los Angeles, CA
USA;

Department of Neurology
David Geffen School of Medicine at UCLA and Ronald Reagan
UCLA Medical Center
Los Angeles, CA
USA

Karen M. Weidenheim

Department of Pathology (Neuropathology)
Montefiore Medical Center
Albert Einstein College of Medicine
Bronx, NY
USA

Sarah Wiethoff

Department of Molecular Neuroscience
UCL Institute of Neurology
University College London
London
UK;

Center for Neurology and Hertie Institute for Clinical Brain
Research Eberhard-Karls-University
Tübingen
Germany

Krystina E. Wisniewski

Deceased

Anthony T. Yachnis

Department of Pathology, Immunology, and Laboratory
Medicine
University of Florida College of Medicine
Gainesville, FL
USA

Introduction

In the preface to the first edition of this book, published in 2004, we remarked that the extraordinary advances in understanding the molecular and cellular basis of neurodevelopment had shepherded in a new era for neuropathology. We considered that to have been an opportune time to advance this book in a series devoted to pathology and genetics.

This premise stands even stronger today. Over the past nearly decade and a half, new discoveries in metabolic pathways, molecular genetics, and developmental biology have again leapfrogged our knowledge regarding numerous inherited and acquired disorders of the developing and immature nervous system.

We hope this second edition will continue to be a useful guide to practicing neuropathologists, pediatric pathologists, general pathologists, and neurologists in deciphering the pathology and pathogenesis of the usually complex disorders affecting the nervous system of the embryo, fetus, and child.

In this era of molecular diagnostics, advanced imaging, and prenatal screening, it is true that the neuropathologist is being asked to evaluate many fewer children with nervous system

It has been a great pleasure working on this second edition of the ISN series “Developmental Neuropathology, Pathology and Genetics” which has been expertly planned and executed by our colleagues and friends, Homa Adle-Biasette, Brian Harding and Jeffrey Golden. The contributors from several continents make it truly international, and we wish to thank everyone for their patience with unforeseen delays, and for their generosity in providing their time and sharing their material for this

abnormalities described in this text. This is precisely why this book is needed; to help to guide those individuals who are asked to evaluate these infrequently seen cases that are so important to understand for families and future decisions they will have to make.

We have once again been assisted by an astounding cadre of international experts who have provided succinct and well-organized chapters. The wealth of knowledge in this field has once again necessitated some selectivity and brevity to maintain short and easily navigable chapters.

Given the continued pace of discovery in the fields relevant to this book, we anticipate that new understandings are likely even at the time of this publication. We hope that this book provides a practical guide to diagnosing and understanding disorders affecting this vulnerable population and potentially stimulates further advances in this exciting area.

Homa Adle-Biasette
Brian Harding
Jeffrey Golden

book. We also acknowledge those authors, some now retired, who contributed to the first edition. Special thanks to Claire Bonnett, Prerna Sanjay, and Atiqah Abdul Manaf of John Wiley, for technical expertise and help with production.

Françoise Gray
Catherine (Katy) Keohane
ISN Book Series Co-Editors

1

Central Nervous System Manifestations of Chromosomal Change

Joseph R. Siebert

Department of Laboratories, Seattle Children's Hospital and Departments of Pathology and Pediatrics, University of Washington, Seattle, WA, USA

Introduction

A wide variety of morphologic and functional abnormalities have been identified in the central nervous systems (CNS) of patients with chromosomal defects. These are reviewed for the more commonly encountered karyotypes, with emphasis given to those aberrations in chromosome number (e.g., trisomy, monosomy) or chromosome morphology (i.e., large deletions and duplications) that affect the CNS. Disorders associated with mosaicism, lesser chromosomal changes (including translocations), or single gene mutations are not included.

Chromosomal changes are encountered in early pregnancy loss, but their true incidence is hard to determine. A commonly used estimate is 50%. Alterations like trisomy 16 (estimated to occur in 1% of all conceptuses) are unlikely to come to the attention of neuropathologists because of early fetal demise. The prevalence of chromosomal defects is summarized for common CNS anomalies in Table 1.1. Because of genetic mechanisms (e.g., incomplete penetrance and variable expressivity) and other factors, phenotypes do not always correlate precisely with specific karyotypes. For this reason, the tables in this chapter are limited to general summaries.

The craniofacial complex

While this chapter is oriented toward the description of changes in the CNS, the cranium can scarcely be ignored. The embryogenesis of brain and cranium proceeds in tandem and anomalies of one structure are almost always reflected by changes in the other.

The pathologist whose study of the CNS is hampered by severe autolysis, commonplace in stillbirth, or delivery by dilatation

and evacuation, does well to examine the cranium to get clues to CNS pathology [1]. Two examples are anencephaly and holoprosencephaly. In the former, the cranial base is markedly flattened, much of the calvaria is absent, and sphenoidal anomalies are common. In specimens altered by holoprosencephaly, the anterior cranial fossa is flattened, cribriform plates are small, obscured, or absent, the crista galli is reduced in size or absent, and the anterior falx cerebri is absent or hypoplastic (Figure 1.1). Axial anomalies are especially common in trisomy 13 and 18. Identifying any of these changes is of great help in achieving a diagnosis, or at least in attempting to corroborate prenatal imaging studies.

Genetic counseling and the neuropathologist

Affected individuals and/or their families desire to understand both present and future issues surrounding their condition. Families are concerned about implications for present and future care, as well as prevention, recurrence risk, and family planning. Neuropathologists should be integral members of the team that provides information to patients and their families. Specialists will serve their patients well by providing information that is of direct use to the genetic counselor. In addition to written reports, the pathologist should provide photographs, especially of external phenotypic features (face, head, hands, and so forth), that have diagnostic value. Ethical ramifications are considerable, but beyond the scope of this review.

Autosomal trisomy

A trisomic cell is defined by the presence of three homologous chromosomes. The condition is serious and often associated

Table 1.1 Prevalence of chromosomal abnormalities in common central nervous system (CNS) anomalies.

CNS anomaly	Estimated Prevalence of Abnormal Karyotype (%)	Predominant Karyotypic Abnormality	Reference
Anencephaly	9	Variable, including trisomy 13, 18, and triploidy	26
Holoprosencephaly	50	Trisomy 13, 18	27
Dandy-Walker malformation	45–55	Trisomy 9, 13, 18, 21; triploidy; del(6p)	28
Complete vermian agenesis	32		28
Inferior vermian agenesis	53		28
Chiari malformation	Occasional	Trisomy 13, 18	26
Microcephaly/micrencephaly	Frequent	Trisomy 9, 13, 18, 21; sex chromosome trisomy or monosomy	26
Isolated ventriculomegaly	12	Trisomy 21; 47XXY	29
Agenesis of corpus callosum	18	Trisomy 8, 13, 18; del(11q)	26,30
Spina bifida/myelomeningocele	17	Trisomy 13, 18; triploidy	31
Coloboma	Often unspecified; 10% in 1993 study	Trisomy 13, 18; triploidy; 5p-, 4p-	32
Micro-/anophthalmia	25+	Trisomy 13	33

with prenatal demise, or live birth with multiple anomalies, some of which are life-threatening. Females with trisomy 13 or 18 have severe ovarian dysgenesis, resulting germ cell failure, and cannot reproduce, should they survive to reproductive age [2]. Women with trisomy 21 who become pregnant give birth to infants with trisomy 21 in about one-third of cases; affected males are sterile. Trisomic conditions with associated changes of the craniofacial complex and CNS are described below and summarized in Table 1.2.

Trisomy 8

Complete trisomy 8 is observed in first-trimester terminations of pregnancy and rarely thereafter. By contrast, survival to term

or beyond with mosaic trisomy 8 is more common. The severity of phenotypic change does not appear to depend upon the percentage of trisomic cells, and thus, the phenotypes of complete and mosaic trisomy 8 are similar. The frequency is estimated to be between 1:25 000 and 1:50 000 live individuals; males are five times more commonly affected. Patients may manifest psychomotor restriction, seizures, or personality disorders; they have dysmorphic facies, with prominent forehead, widely spaced and deeply set eyes, broad nasal root, micrognathia, thick lips, and large protuberant ears [3]. Agenesis or hypoplasia of the corpus callosum is the chief alteration of the CNS; spina bifida occulta is observed, as well as a number of less common malformations.

Trisomy 9

Most newborns with trisomy 9 die in the perinatal period. Survivors have mental and motor deficiencies, and fail to thrive. Variable degrees of mosaicism are thought to modulate the severity of changes noted in the condition. The CNS is abnormal most of the time, and most consistently shows a Dandy-Walker malformation, although it has been well characterized morphologically in only a few cases [4]. Craniofacial changes may be nonspecific or those associated with holoprosencephaly.

Trisomy 13

Trisomy 13 is the third most common autosomal trisomy, with a prevalence variably reported as 1:5000 to 1:29 000 live births [5]. Like other aneuploid conditions, the spontaneous death rate is increased dramatically, both prenatally and perinatally; mean postnatal survival is 2.5–4 days. Diploid-aneuploid mosaicism confined to the placenta may affect intrauterine survival, and, inexplicably, mothers often suffer preeclampsia, which may contribute to spontaneous pregnancy loss [6].




Figure 1.1 Close view of cranial base, showing anterior and middle cranial fossae of patient with holoprosencephaly and trisomy 13. Note absence of ethmoid derivatives (crista galli, cribriform plates) and falx cerebri. In cases of ocular hypotelorism, the basisphenoid and sella turcica may be narrowed.

Table 1.2 Craniocerebral findings in selected autosomal aneuploid conditions.

Karyotype	Craniofacial Findings	Morphologic and Functional Abnormalities of CNS
Trisomy 8	Scaphocephaly; prominent forehead; ocular hypertelorism; deeply set eyes; bulbous nose; thickened, everted lower lip; high or cleft palate; low set, dysplastic ears; micrognathia	Variable psychomotor restriction; personality disorder/psychosis; agenesis of the corpus callosum; spina bifida occulta; less frequent CNS changes: aqueductal stenosis; abnormal falx cerebri; Dandy–Walker malformation or isolated hypoplastic cerebellum; eye changes (variable): microphthalmia; strabismus; coloboma; corneal/lens opacity; glaucoma
Trisomy 9	Microcephaly, dolichocephaly; widening of cranial sutures; deep-set eyes; small palpebral fissures; bulbous nose, with broad base; low set, anomalous ears; micrognathia	Growth restriction; Dandy–Walker malformation; holoprosencephaly; lissencephaly; ventriculomegaly/hydrocephalus; agenesis of corpus callosum; hypoplasia of septum pellucidum; cortical migration anomalies (including subpial glial nodules, pachygyria); simplified inferior olivary nuclei, abnormal hippocampal formation; germinal matrix cysts; syringomyelia; myelomeningocele; eye changes: anophthalmia; retinal or iridal coloboma; hypoplasia of optic nerves
Trisomy 13 (Patau syndrome)	Microcephaly; trigonocephaly; holoprosencephalic facies (e.g., cleft lip/palate; cebocephaly; ethmocephaly; cyclopia); cutaneous scalp defects; dysplastic ears	Holoprosencephaly (most common); Chiari malformation; hypoplastic cerebellum; neuronal migration defects; spina bifida; eye changes: microphthalmia; coloboma; retinal dysplasia; aniridia; hypoplastic optic nerve
Trisomy 18 (Edwards syndrome)	Microcephaly; ‘strawberry-shaped’ skull; broad, high forehead; low set, dysplastic ears and temporal bone anomalies; small nose and mouth; choanal atresia; cleft lip/palate; micrognathia	Partial or complete absence of the corpus callosum; Chiari malformation; neural tube defects (myelomeningocele, anencephaly); holoprosencephaly; neuronal migration defects; choroid plexus cysts; eye changes (less common): coloboma; cataract; cloudy cornea; retinal hypopigmentation; microphthalmia; iridal hypoplasia
Trisomy 21 (Down syndrome)	Incomplete ossification of calvaria; hypertelorism; cleft lip and/or palate; micrognathia; low set, malformed ears	Hydrocephalus, holoprosencephaly, hypoplasia of basal ganglia, cerebellum, occipital lobes, or other focal structure; lumbar myelomeningocele; less often: Chiari or Dandy–Walker malformation, hydranencephaly. Eyes: ocular coloboma, microphthalmia, anophthalmia, corneal clouding, cataract
Triploidy (69,XXX or 69,XXY)	Incomplete ossification of calvaria, with enlarged fontanelles; facial dysmorphism associated with holoprosencephaly; ‘Harlequin’ orbits; low nasal bridge; choanal atresia; preauricular malformations; cleft lip/palate	Intrauterine growth restriction; all varieties of holoprosencephaly; hydrocephalus; hydranencephaly; hypoplasia of basal ganglia, occipital lobes, or cerebellum; choroid plexus cysts; cavum septi pellucidi; less common: Chiari or Dandy–Walker malformation; eye changes: micro- or anophthalmia; proptosis; hypoplasia of iris or retina; coloboma; corneal clouding; cataract
Tetraploidy (92,XXXX or 92,XXYY)	Microcephaly; prominent, narrow forehead; low set ears; preauricular ear tags; beaked nose; micrognathia; cleft lip/palate	Severe pre- and postnatal growth restriction; severe mental restriction; hydrocephalus; Chiari malformation; myelomeningocele; arhinencephaly; eye changes: micro- or anophthalmia; cloudy cornea; coloboma

CNS, central nervous system

Phenotypic changes are well recognized (Table 1.2) and involve the CNS (Figures 1.2, 1.3, 1.4), craniofacial complex, axial skeleton, and multiple extracranial tissues. The most common CNS manifestations among this group are holoprosencephaly and anencephaly.

Trisomy 18

The incidence of trisomy 18 is given as 0.3 per 1000 live births, with a female to male ratio of 3:1. Cranial and brain

abnormalities are common, as are eye malformations, axial, hypophyseal, and extracranial anomalies [3].

Trisomy 21

The literature on Down syndrome and descriptions of CNS changes are voluminous, although probably not entirely reliable, in that older cases were not confirmed by karyotyping. Because phenotypic variability is substantial, diagnosis is not always possible by physical examination, especially in the




Figure 1.2 Two term infants with trisomy 13. (a) Superior view of calvaria (after reflection of scalp) altered by trigonocephaly and partial metopic craniosynostosis. (b) Basal view of deformed brain from patient with trigonocephaly; note absence of olfactory tracts (arhinencephaly), asymmetric optic nerves, and dysplastic cerebellar folia.




Figure 1.3 Infant with trisomy 13. (a) Basal view of brain with holoprosencephaly. (b) superior view of same brain. Note fusion of frontal lobes and lateral ventricles.




Figure 1.4 Coloboma is encountered frequently in patients with chromosomal abnormalities. Iridal colobomata are shown from a newborn infant with classic findings of trisomy 13.

prenatal period. The condition is rather common, with estimates generally given at about 1.3 per 1000 live births. About 95% of patients have 47,+21 karyotypes, while the remainder are mosaic or manifest unbalanced translocations (mostly Robertsonian).

The cranium is round (brachycephaly) and the brain likewise, with foreshortened frontal poles and a flattened occiput; the superior temporal gyrus is often small and straight (Figure 1.5). Brain weight is usually reduced by 20–25% after the first 2 years. A variety of dendritic abnormalities have been identified. The most consistent findings are reduced complexity and numbers of dendritic branches and spines after 1–2 years of age. Patients suffer early dementia leading to Alzheimer-type changes in the brain.




Figure 1.5 Lateral view of brain of newborn infant with trisomy 21. Note mild blunting of frontal lobe and abnormally small superior temporal gyrus, common findings in this condition. The middle temporal gyrus is enlarged.

Other autosomal aneuploidies

Triploidy

The most common chromosomal abnormality observed in first-trimester spontaneous miscarriages is a complete, supernumerary set of chromosomes, or triploidy, occurring in 12% of all such fetuses. Affected individuals (69,XXX or 69,XXY), who may be mosaic or manifest complete trisomy, survive occasionally to term, then die in the immediate postnatal period. Increased nuchal translucency and characteristic placental abnormalities (enlarged placenta with hydatidiform degeneration, or a small placenta in cases of digyny (i.e., a diploid ovum fertilized by a monoploid sperm), are noted by prenatal ultrasound. Intrauterine growth restriction is also common, as are a wide variety of well-known craniofacial, CNS (Figures 1.6 and 1.7), and extracranial anomalies. Syndactyly of the third and fourth fingers, or first and second or third and fourth toes, occurs in 50% and 30% of individuals, respectively, and should compel



Figure 1.6 Median section of cerebellum and brainstem altered by Chiari malformation. Note small size of cerebellum and caudal herniation of the cerebellum and medulla, unrolled posterior medullary velum, beaking of colliculi, and herniation of brainstem; the fourth ventricle is nearly obliterated.




Figure 1.7 Dandy–Walker malformation. (a) In situ demonstration of absent cerebellar vermis. (b) Horizontal section of cerebellum, with midline space representing absence of vermis.

the pathologist to obtain a karyotype. Tissue other than blood should be cultured, as triploid cells are eliminated selectively from lymphocytes. Flow cytometry is an efficient way of reaching a diagnosis, in that the quantity of DNA measured by the process will be increased by 50%.

Tetraploidy

Like triploidy, tetraploidy (92,XXXX or 92,XXYY) is also associated with early loss. Together, the two conditions account for 30% of karyotypically abnormal spontaneous miscarriages. Growth and mental restriction and a wide variety of craniofacial and CNS anomalies are found in affected patients.

Sex chromosome aneuploidy

Patients with alterations in the number of X or Y chromosomes oftentimes manifest normal development. However, an increased risk for gonadal dysgenesis and decreased fertility are also recognized, as is developmental delay involving speech, motor abilities, and learning. Phenotype, including behavior, is affected in patients with sex chromosome aneuploidies, but the severity does not correlate with the magnitude of aneuploidy. Mental restriction, schizophrenia, and bipolar disorders have all been associated variably with sex chromosome aneuploidy. It is impossible to assign prognosis with certainty. Although specific neuropathological changes are not well defined, sporadic anomalies are reported and summarized in Table 1.3.

Deletions

Deletions arise from a variety of mechanisms. They involve absence of the terminal or interstitial regions of the chromosome, leaving a haploid DNA content for the affected segment, and for this reason were referred to as “monosomy” in older

citations. Deletions may appear de novo as isolated anomalies, may result from de novo inversions, or may be inherited as familial translocations or inversions. The magnitude of phenotypic or functional deficit may or may not correlate with the size of deletion. The recurrence risk for deletion syndromes in siblings is generally negligible, unless a parent is a translocation carrier. Offspring of balanced translocation carriers may inherit balanced translocations or deletion (or duplication) syndromes. Carriers of balanced translocations do not, as a rule, have severely altered phenotypes. Affected patients, if able to reproduce, may transmit deletions.

The absence of genetic material has, in some instances, compelled researchers to hypothesize haploinsufficiency as a pathogenetic mechanism. Clearly, knowledge of breakpoints and exact genes that are lost is important to understanding genotype/phenotype correlations. The contribution of subtelomeric deletions to CNS development and function is important. Patients with terminal deletions may exhibit phenotypes that differ from those with interstitial phenotypes. General statements regarding the more common deletion syndromes, with anatomic and functional details, are provided in Table 1.4.

Deletion 3p-

Patients with 3p- deletions are rare and have an equal sex ratio. Growth restriction and developmental delay are major findings, and, like patients with many deletions, survival depends upon the severity of anomalies. The gene *MEGAP* is lost in 3p- and this gene is thought to play an important role in cognition, learning, and memory, presumably by regulating the cytoskeleton, axonal branching, and neuronal migration [7].

Deletion 4p-

Patients with deletions of the short arm of chromosome 4 (Wolf-Hirschhorn syndrome) occur infrequently (1:50 000 live births), with a female: male ratio of 2:1. Infants may manifest intrauterine growth restriction and hypotonia at birth; 35% die in the

Table 1.3 Craniocerebral findings in selected sex chromosome aneuploidies.

Karyotype	Craniofacial Findings	Morphologic and Functional Abnormalities of CNS
45, X0 (Turner syndrome or Ullrich-Turner syndrome)	Facies without expression; low posterior hairline; ocular hypertelorism; downslanting palpebral fissures	Pre- and postnatal growth restriction; eye changes (frequent): strabismus; ptosis; learning difficulties, including visual-spatial and perceptive deficits; psychiatric impediments, but no psychopathology
47,XXX (triple-X or trisomy X)	Often phenotypically normal (tall stature common); uncommon dysmorphic features: ocular hypertelorism; epicanthal folds; depressed nasal bridge	Poor motor skills; learning disabilities and language delay in some patients; mental restriction possible, but highly variable
47,YYY	Often phenotypically normal (tall stature common); increased craniofacial dimensions by cephalometry	Learning disabilities, including speech delay and autism; behavioral delay is inconsistent; hyperactivity; increased risk for schizophrenia or bipolar disorder; intention tremor; hypotonia; hypoplastic or absent corpus callosum; ventriculomegaly; Dandy-Walker malformation
47,XXY (Klinefelter syndrome)	Feminization; tall stature	Normal intelligence quotient, but reading deficiency and poor spelling in two-thirds of patients; reduced control of impulses and poor motor coordination; dyslexia, attention-deficit disorder, or psychiatric disorders, including psychosis, in some
48,XXXX (tetra-X s. or tetrasomy X)	Tall stature; dull, flat facial expression; ocular hypertelorism; flat nasal bridge; epicanthal folds	Intrauterine growth restriction; mild to moderate mental restriction; emotional disturbances; eye changes: strabismus, iridal coloboma; myopia
49,XXXXX (penta-X s. or pentasomy X)	Microcephaly; coarse facies, with epicanthal folds; upslanting palpebral fissures; broad, depressed nasal bridge; ocular hypertelorism; low set, malformed ears; low posterior hairline; cleft palate; micrognathia	Growth restriction (uncommon); severe psychomotor restriction
49,XXXXY	Microcephaly; plagiocephaly; trigonocephaly; many traits shared with pentasomy X, including: epicanthal folds; upslanting palpebral fissures; ocular hypertelorism; midface hypoplasia; low nasal bridge; cleft soft palate; micrognathia	Intrauterine and postnatal growth restriction; delayed ossification; mental restriction; psychomotor delay; psychiatric/personality disorders, including cognitive impairment; aggressiveness, self-inflicted injury; severely delayed or absent speech

CNS, central nervous system

first 2 years of life. Survivors have seizures that can be constant and severe psychomotor restriction; they have been described as being without personality. It is possible, however, that the condition is more common than previous estimates. It has probably been misdiagnosed at times (for example, midline scalp defects, facial clefts, and coloboma in a subset of patients may be confused with trisomy 13) and only about one-half are recognized by routine banding techniques [8]. Thus, prognosis may not be as poor as believed previously. Only a few adults have been described, but accurate diagnosis facilitates appropriate interventional care and counseling.

Deletion 5p-

Commonly known as *cri-du-chat* (“cat cry”) syndrome, deletion 5p- is one of the most common deletion syndromes, occurring in 1:15 000 to 1:50 000 live births and constituting nearly 1% of all institutionalized patients; a slight female preponderance is recognized, with a male to female ratio of 0.72 [3]. Findings evolve as patients age. Infants exhibit a high-pitched or mewing, cat-like cry, which disappears in childhood as the orientation of

posteriorly approximated vocal cords changes. Similarly, the rounded face becomes thinner and more asymmetric. Speech and language development are delayed, sometimes severely.

Deletion 9p-

Deletion 9p- is well defined clinically, with over 100 cases published; a female predilection of 2:3 to 3:4 has been reported [3]. Nonspecific facial dysmorphia, hypotonia (or occasional hypertonia), psychomotor and mental restriction are common, and a particular neurobehavioral profile is recognized. The eyes can slant either upward or downward; infants with the former can be confused with patients with trisomy 21. As with del (5p), facial abnormalities become less obvious with age.

Deletion 11q-

Patients with deletions of the long arm of chromosome 11 (Jacobsen syndrome) manifest psychomotor restriction and a variety of nonspecific changes of the craniofacial complex. Some 32 cases have been reported; the condition has a strong female preponderance. Over one-half of patients manifest a variety of

Table 1.4 Craniocerebral findings in selected deletion syndromes.

Deletion	Craniofacial Findings	Morphologic and Functional Abnormalities of CNS
3p-	Microcephaly; dolichocephaly; synophrys; angulated face; ocular hypertelorism; short, broad nose; low set, dysplastic ears; micrognathia	Pre- and postnatal growth restriction, with severe developmental, psychomotor, and speech delay; ptosis
4p-	Also known as Wolf–Hirschhorn syndrome; microcephaly; dolichocephaly; midline scalp defect; cleft lip and/or palate; ‘Greek helmet’ facies, with ocular hypertelorism; frontal bossing; hypoplastic orbits; epicanthal folds; beaked nose with broad ridge; midline scalp defect; preauricular dimples; small mouth; dental anomalies	Postnatal growth restriction; severe psychomotor restriction; seizures; eye changes: ptosis, strabismus, nystagmus, coloboma
4q-	Microcephaly; abnormal cranial contour; ocular hypertelorism; epicanthal folds; depressed nasal bridge, with anteverted nares; Robin sequence, with cleft lip/palate and retro- or micrognathia; low set, posteriorly rotated, pointed ears	Postnatal growth restriction; mild to moderate mental restriction; hypotonia; seizures; sensorineural hearing loss and oculomotor nerve palsy (latter findings in one patient)
5p-	Also known as <i>cri du chat</i> syndrome; microcephaly; round face, with ocular hypertelorism and low set, posteriorly rotated ears that evolves after infancy to a thin, asymmetric face; epicanthal folds (more common in young); wide, depressed nasal bridge; micrognathia	Severe growth and mental restriction; hypotonia in infancy changes over time to hyperactive reflexes; ventriculomegaly; strabismus; tortuous retinal vessels/optic atrophy in adults
9p-	Trigonocephaly; flattened occiput; depressed temples; ocular hypertelorism, with variably slanted eyes; exophthalmos; microphthalmia; epicanthal folds; low set ears with dysplastic or aplastic lobes; choanal atresia; short nose with flattened bridge; midface hypoplasia, with small mouth; cleft palate; long philtrum	Developmental delay, with variable degree of psychomotor and mental restriction; both hypotonia and hypertonia reported; seizures; autism; hypoplastic corpus callosum; large cisterna magna
11q-	Also known as Jacobsen syndrome; trigonocephaly; telecanthus; ocular hypertelorism; broad, depressed nasal bridge; low set, dysplastic ears; micrognathia; palatal anomalies	Psychomotor restriction, with severe speech impairment; micrencephaly, with white matter deficiency (supratentorial); ventriculomegaly, with or without spina bifida (latter infrequent); cerebral atrophy; agenesis of corpus callosum; eye changes: iris coloboma; strabismus
13q-	Microcephaly; high, broad forehead; large, low set ears; depressed nasal bridge; protruding maxilla; micrognathia	Severe mental restriction and developmental delay; hypotonia; hydrocephalus; hydranencephaly; holoprosencephaly; agenesis of the corpus callosum; neural tube defects (lumbosacral myelomeningocele); eye changes: ptosis; microphthalmia; coloboma (iris or choroid); corneal opacity; cataract; retinoblastoma (in 18% of patients)
18p-	Facial changes may be non-specific (round face, ocular hypertelorism, large ears, broad nasal bridge, upturned nostrils, micrognathia) or those associated with holoprosencephaly (see text); also micro- or brachycephaly; craniostenosis; choanal stenosis, cleft palate	Variable mental restriction; diabetes insipidus; holoprosencephaly; hypotonia; spinal muscular atrophy; aphasia/dysphasia; eye changes: ptosis, strabismus, nystagmus, microphthalmia, coloboma, cloudy cornea, cataract; hearing loss
18q-	Microcephaly; deeply set eyes; narrow/atretic ear canals; frontal bossing; midface hypoplasia; prominent chin; small ‘carp’ mouth	Hypotonia, with classic ‘froglike’ position of legs; mild to severe mental restriction; behavioral changes (see text) and seizures; ventriculomegaly secondary to volume loss and white matter disease (involving basal ganglia and/or thalami); holoprosencephaly; thinning of corpus callosum; hypotonia; hearing impairment; eye changes: strabismus, nystagmus, glaucoma, tapetoretinal degeneration, bilateral optic atrophy
21q-	Microcephaly; holoprosencephaly; downward slanting palpebral fissures; prominent nasal bridge; large, low set ears; cleft lip/palate; micrognathia	Variable growth and mental restriction; hypo- or hypertonia; sensorineural hearing loss; cortical atrophy; hypoplasia of cerebellum/brain stem; agenesis of corpus callosum; ventriculomegaly; eye changes: Peters anomaly of iris; microphthalmia; cataract

CNS, central nervous system

CNS abnormalities; some are structural, but others appear to represent deficient or delayed white matter formation [9]. A host of extracranial malformations are also recognized.

Deletion 13q-

Deletion 13q- is often lethal in early gestation. Surviving patients are rare, presenting in an estimated 2 in 100 000 births, with a gender ratio of 1:1 [10]. Growth restriction is common; mental restriction is moderate to severe [11]. Holoprosencephaly (*ZIC2*, mutated in some cases of holoprosencephaly, maps to 13q), hydranencephaly, and neural tube defects have been reported, and retinoblastoma is recognized commonly [12].

Deletion 18p-

Over 150 cases of deletion 18p- have been reported, with a male to female ratio of 2:3 [3]. Affected individuals show variable degrees of developmental delay and mental restriction, with consistent facial dysmorphism in infants and adults. Extracranial anomalies are variable as well, and include cardiac defects and endocrine dysfunction [13]. Patients with holoprosencephaly may exhibit any of the associated facial changes, including mild facial changes, cleft lip and palate, cebocephaly, and cyclopia. Of note, *TGIF*, one of the genes mutated in holoprosencephaly, maps to 18p. Focal or generalized dystonia and hypokinesia are observed, with distal spinal muscular atrophy reported.

Deletion 18q-

Deletion 18q- is one of the most common deletion syndromes (without sex predilection), and is manifest by tapered digits, facial dysmorphism, including deeply set eyes, dysplastic ears, and small, rounded, “carp” mouth. Hypotonia and growth failure are common. Decreased growth hormone production in patients suggests that a gene on 18q is involved in hormone production [14]. Correlated with this is the report of hypoplasia of the anterior pituitary gland [15]. Fifty to eighty percent of patients have sensorineural or conductive hearing loss, associated with malformations of the external and middle ears [16]. Intelligence is mildly to severely deficient, and behavioral problems include hyperactivity, aggressiveness, and temper tantrums; autism occurs in some patients, but probably not with increased incidence. By magnetic resonance imaging, white matter abnormalities involve periventricular and deep white regions (more pronounced in parieto-occipital areas), internal and external capsules, centrum semiovale, corona radiata, and subcortical regions. Changes are thought to result from incomplete myelination, most probably due to a missing copy (haploinsufficiency) of the myelin basic protein gene [17].

Deletion 21q-

Deletion 21q- has been called the “phenotypic countertype of trisomy 21,” in that studies of affected patients who have reduced amounts of genetic material from chromosome 21 might shed light on those with increased amounts of material (i.e., those

with Down syndrome). Phenotypic variation is considerable, and it is possible that a variety of conditions, including monosomy 21, have been reported inappropriately under this designation [3]. That being said, complete monosomy 21 is very rare, and phenotypic alterations probably arise from absence of the long arm [18]. Many findings are nonspecific [19].

Duplications

Pure duplications are rare. More likely, they result from unbalanced translocations, in which case, the duplication of material on one chromosome is accompanied by a deletion on another chromosome. This makes it difficult to attribute a given phenotype solely to the duplication. Selected syndromes are presented below, with specific findings provided in Table 1.5.

Duplication 3q+

Duplication 3q+ is a rare condition, known by about 40 published cases; it can resemble Cornelia de Lange syndrome. The male to female ratio is equal. A wide variety of craniofacial and CNS anomalies and functional alterations are recognized. The fingers can be held in a “trisomy 18 position” which can be confusing to the examiner [20]. The pure dup (3q) syndrome is rare, in part because most patients with the syndrome have unbalanced translocations, the deletion on another chromosome complicating analysis [21]. Affected patients have an extra copy of the *KCNMB3* gene, which shows sequence similarities to regulatory subunits of calcium-activated potassium channels; because of the importance of these channels in neuronal function, it is possible that overexpression is related to the seizures and restriction observed in patients [22]. Congenital heart defects are recognized.

Duplication 9p+

Duplication 9p+ is one of the most common partial trisomy syndromes, and is also known as Rethoré syndrome. Individuals have well-recognized features, of which ventriculomegaly and Dandy-Walker malformation (Figure 1.7) are prominent [23]. In fact, the prevalence of Dandy-Walker malformation in this condition has compelled some to suggest a dosage effect of genes located on chromosome 9 [24]. Abnormalities in neuronal migration are also recognized, including subcortical laminar (band) heterotopia or double cortex. The 100 or so cases known have occurred twice as often in females. A generalized delay in bone maturation is manifest by failure of timely closure of fontanelles and cranial sutures; however, catch-up growth often occurs [3]. Findings from magnetic resonance imaging in the single reported adult consist of underdeveloped white matter, atrophic corpus callosum, and choroidal fissure cyst [25].

Table 1.5 Craniocerebral findings in selected duplication syndromes.

Duplication	Craniofacial Findings	Morphologic and Functional Abnormalities of CNS
3q+	Microcephaly; brachycephaly or dolichocephaly; craniosynostosis or widely separated sutures, with large anterior fontanelle; hypertrichosis/synophrys/bushy eyebrows/long eyelashes; ocular hypertelorism; upslanted palpebral fissures; low set, malformed ears; broad nasal root; cleft palate; prominent philtrum; prognathism; micro- or retrognathia	Severe growth and mental restriction; seizures; micrencephaly; polymicrogyria; hypoplastic olfactory bulbs and tracts or arhinencephaly; cerebellar hypoplasia; hypoplastic corpus callosum; neuronal migrational defects; ventriculomegaly; aqueductal stenosis; hypoplastic pons; hypoplastic pyramidal tracts; gross spinal cord anomalies, including anomalous fissures, narrowing, or shortening; eye changes: strabismus; ptosis; microphthalmia; anophthalmia; cataract; coloboma; glaucoma
4p+	Microcephaly; prominent glabella/supraorbital ridge; ocular hypertelorism; bulbous nose, with depressed nasal bridge; ear abnormalities; prominent chin	Psychomotor restriction; postnatal growth restriction; seizures; respiratory and feeding problems; eye changes: anomalies reported (unspecified)
9p+	Also known as Rethoré syndrome; microcephaly; brachycephaly; delayed closure of fontanelles and cranial sutures; frontal bossing; ocular hypertelorism; deep-set, downslanting eyes; broad nose; large, low set, dysplastic ears; short, upper lip; cleft lip/palate; downturned corners of mouth	Mild to moderate developmental delay, especially language; variable mental restriction; hypotonia; Dandy-Walker malformation; ventriculomegaly/hydrocephalus (sometimes associated with seizures); aqueductal stenosis; polymicrogyria; subcortical band heterotopia (in one adult); underdeveloped white matter; hypoplastic corpus callosum; choroidal fissure cyst; eye changes: microphthalmia; Brushfield spots; keratoconus; strabismus; myopia; cataract; iridal coloboma; ectopic pupil/dislocated lens; optic nerve atrophy
10q+	Microcephaly; high forehead; small palpebral fissures; flat, broad nasal bridge; small upturned nose; midface hypoplasia; prominent philtrum; cleft palate; micrognathia; small mouth	Profound psychomotor and developmental delay; pre- and postnatal restriction; eye changes: blepharophimosis; scoliosis
15q+	Microcephaly; dolichocephaly; prominent occiput; downslanting palpebral fissures; large, low set ears; bulbous nose; long philtrum; small mouth, with micro- or retrognathia	Severe developmental delay, with postnatal growth restriction due in part to swallowing difficulties; distal 15q duplication may manifest hydrocephaly rather than microcephaly

CNS, central nervous system

Future perspective, conclusions

Clearly, a wide variety of morphologic and functional deficits affect the CNS of patients with chromosomal abnormalities. These changes are recognized in some detail, and continue to be delineated. However, while some embryologic and even genetic mechanisms are beginning to be identified, most conditions are poorly understood, and little is known about genotype/phenotype correlations. It will require the continue efforts of clinical workers and researchers alike to bring understanding and, it is hoped, prevention or cures to patients and their families.

References

- Siebert JR, Kapur RJ (2000) Congenital anomalies in the fetus: Approaches to examination and diagnosis. *Pathol Case Rev* 5:3–13
- Cunniff C, Jones KL, Benirschke K (1991) Ovarian dysgenesis in individuals with chromosomal abnormalities. *Hum Genet* 86:552–6
- Schinzel A (2001) *Catalogue of unbalanced chromosome aberrations in man*, 2nd ed., New York, Walter de Gruyter
- Golden JA, Schoene WC (1993) Central nervous system malformations in trisomy 9. *J Neuropathol Exp Neurol* 52:71–7
- Goldstein H, Nielsen KG (1988) Rates and survival of individuals with trisomy 13 and 18. *Clin Genet* 34:366–72
- Kalousek DK, Barrett IJ, McGillivray BC (1989) Placental mosaicism and intrauterine survival of trisomies 13 and 18. *Am J Hum Genet* 44:338–43
- Heath RJW, Insall RH (2008) Dictyostelium MEGAPs: F-BAR domain proteins that regulate motility and membrane tubulation in contractile vacuoles. *J Cell Science* 121:1054–64
- Battaglia A, Carey JC, Wright TJ (2001) Wolf-Hirschhorn (4p) syndrome. *Adv Pediatr* 48:75–113
- Mattina T, Perrotta CS, Grossfeld P (2009) Jacobsen syndrome. *Orphanet J Rare Dis* 4:9
- Russell LF (1990) In: ML Buyse, ed., *Birth Defects Encyclopedia*, Dover, Center for Birth Defects Information Services, pp. 366–7
- Stoll C, Alembik Y (1998) A patient with 13q- syndrome with mild mental retardation and with growth retardation. *Ann Genet* 41: 209–12

12. Ballarati L, Rossi E, Bonati MT *et al.* (2007) 13q deletion and central nervous system anomalies: Further insights from karyotype-phenotype analyses of 14 patients. *J Med Genet* 44:e60
13. Sebold C, Soileau B, Heard P *et al.* (2015) Whole arm deletions of 18p: medical and developmental effects. *Am J Med Genet A* 167A:313–23
14. Ghidoni PD, Hale DE, Cody JD *et al.* (1997) Growth hormone deficiency associated in the 18q deletion syndrome. *Am J Med Genet* 69:7–12
15. Bekiesinska-Figatowska M, Walecki J (2001) MRI of the hypophysis in a patient with the 18q-syndrome. *Neuroradiology* 43:875–6
16. Jayarajan V, Swan IR, Patton MA (2000) Hearing impairment in 18q deletion syndrome. *J Laryngol Otolaryngology* 114:963–6
17. Gay CT, Hardies LJ, Rauch RA *et al.* (1997) Magnetic resonance imaging demonstrates incomplete myelination in 18q-syndrome: evidence for myelin basic protein haploinsufficiency. *Am J Med Genet* 74:422–31
18. Curry CJR (1990) Chromosome 21, monosomy 21. In: ML Buyse, ed., *Birth Defects Encyclopedia*. Dover, MA, Center for Birth Defects Information Services in association with Blackwell Scientific. p. 390
19. Wakui K, Toyoda A, Kubota T *et al.* (2002) Familial 14-Mb deletion at 21q11.2-q21.3 and variable phenotypic expression. *J Hum Genet* 47:511–16
20. Steinbach P, Adkins WN, Caspar H *et al.* (1981) The dup(3q) syndrome: report of eight cases and review of the literature. *Am J Med Genet* 10:159–77
21. Faas BH, De Vries BB, Van Es-Van Gaal J *et al.* (2002) A new case of dup(3q) syndrome due to a pure duplication of 3qter. *Clin Genet* 62:315–20
22. Riazi MA, Brinkman-Mills P, Johnson A *et al.* (1999) Identification of a putative regulatory subunit of a calcium-activated potassium channel in the dup (3q) syndrome region and a related sequence on 22q11. *Genomics* 62:90–4
23. Chen CP, Chang TY, Shih JC *et al.* (2002) Prenatal diagnosis of the Dandy-Walker malformation and ventriculomegaly associated with partial trisomy 9p and distal 12p deletion. *Prenat Diagn* 22: 1063–6
24. Von Kaisenberg CS, Caliebe A, Krams M *et al.* (2000) Absence of 9q22-9qter in trisomy 9 does not prevent a Dandy-Walker phenotype. *Am J Med Genet* 18:425–8
25. Stern JM (1996) The epilepsy of trisomy 9p. *Neurology* 47:821–4
26. Norman MG, McGillivray BC, Kalousek DK *et al.* (1995) *Congenital malformations of the brain*. New York, Oxford University Press
27. Siebert JR, Cohen MM, Jr, Sulik KK *et al.* (1990) *Holoprosencephaly: An overview and atlas of cases*. New York, Wiley-Liss
28. Chang MC, Russell SA, Callen PW *et al.* (1994) Sonographic detection of inferior vermian agenesis in Dandy-Walker malformations: Prognostic implications. *Radiology* 193:765–70
29. Tomlinson MW, Treadwell MC, Bottoms SF (1997) Isolated mild ventriculomegaly: Associated karyotypic abnormalities and in utero observations. *J Matern Fetal Med* 6:241–4
30. Santo S, D'Antonio F, Homfray T *et al.* (2012) Counseling in fetal medicine: agenesis of the corpus callosum. *Ultrasound Obstet Gynecol* 40:513–2
31. Babcock CJ, Goldstein R, Filly R (1995) Prenatally detected fetal myelomeningocele: is karyotype analysis warranted? *Radiology* 194:491–4
32. Leppig KA, Pagon RA (1993) Phenotypic correlations of ocular coloboma without known cause. *Clin Dysmorphol* 2:322–31
33. Kallen B, Robert E, Harris J (1996) The descriptive epidemiology of anophthalmia and microphthalmia. *Int J Epidemiol* 25: 1009–16

2

Neural Tube Defects

Andrew J. Copp¹ and Brian N. Harding²

¹ Newlife Birth Defects Centre, Institute of Child Health, University College London, UK

² Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA

Definition

Neural tube defects (NTDs) are common congenital malformations of the central nervous system and axial skeleton. They are considered here in three groups.

1. Failure of neural tube closure: Craniorachischisis denotes the almost complete absence of neural tube closure, affecting both brain and spinal cord. Exencephaly, seen only in embryos and early fetuses, describes persistently open and exposed cranial neural folds. Anencephaly results from neuroepithelial degeneration, with absence of the skull vault. Myelomeningocele (syn. open spina bifida) results from failure of closure of the spinal neural tube, most often in the lumbosacral region. The open spinal cord or neural 'placode' is often associated with a protrusion of meninges through the open vertebral defect (spina bifida 'cystica'). Alternatively, the open spinal cord is a flat open lesion, without meningeal sac (myelocele).

2. Primary abnormalities of skeletal development: Encephalocele is a herniation of the brain through an opening in the skull, while protrusion of meninges from the vertebral column is a meningocele.

3. Disorders of secondary neurulation: Spinal dysraphism refers to skin-covered abnormalities of the spinal cord, usually in the low lumbar and sacral regions. These include diplomyelia, a duplicated cord, diastatomyelia, a split cord, and hydromyelia, where the central canal is distended. An associated fatty tissue deposit is termed lipomeningocele (syn. spinal lipoma), often implicated with tethering of the spinal cord.

Normal embryology

Neural tube closure

Neurulation is conventionally divided into primary and secondary phases. Primary neurulation begins with the induction

of the neural plate, a thickened dorsal midline ectodermal structure. The edges of the neural plate then elevate, beginning at about 17–18 days post-fertilization, defining a longitudinal neural groove that deepens with progressive elevation of the sides of the neural plate. The neural folds converge toward the midline and fuse, forming the neural tube, beginning at the future cervical/occipital boundary (designated Closure 1, Figure 2.1) on day 22. Fusion proceeds in cranial and caudal directions from this level. Studies in the mouse have shown that fusion occurs separately, soon after this initial closure, at two other sites within the developing brain. Closure 2 is situated at the forebrain/midbrain boundary, and Closure 3 occurs at the extreme rostral end of the neural plate. Closure of the cranial neural tube then proceeds between Closures 1, 2 and 3 to complete brain neurulation. Fusion spreads simultaneously along the future spinal region from the site of Closure 1, and is completed with closure of the posterior neuropore in the upper sacral region around days 26–28 (Figure 2.1).

It has been demonstrated in mice that the different types of NTDs arise from failure of the varying components of the neurulation sequence. Disruption of Closure 1 results in craniorachischisis, whereas defective Closures 2 or 3, or failure of closure of the anterior or hindbrain neuropores, leads to the varying types of exencephaly, and subsequently anencephaly. Failure of completion of closure at the posterior neuropore results in an open spina bifida (myelomeningocele).

Multi-site neurulation has also been suggested to occur in human embryos, on the basis that it might explain the variation in level of the body axis affected by NTDs in different individuals [1]. However, while direct studies of neurulation-stage human embryos have confirmed the occurrence of events similar to Closures 1 and 3 (Figure 2.1), the balance of evidence suggests there is no human neurulation event corresponding to mouse Closure 2 [2]. In fact, Closure 2 is not obligatory for successful brain neurulation, even in mice: this closure point is absent from




Figure 2.1 Events of neural tube closure in the human embryo and the main types of neural tube defects arising from disorders of neurulation. Closures 1 and 3 are sites of de novo initiation of fusion of the neural folds. Closure 2, which occurs at the forebrain–midbrain boundary in mouse embryos, is absent from human neurulation. Neural tube closure spreads between these sites with completion of closure at the rostral (or anterior), and caudal (or posterior) neuropores. The tail

bud (green shaded region) contains a bi-potential neuromesodermal precursor cell population that gives rise to the sacral and caudal neural tube, through the process of secondary neurulation. These morphogenetic events occur sequentially between days 22 and 28 post-fertilization but, for purposes of clarity, have been projected onto a drawing of a late neurulation-stage embryo (reproduced with permission from *Lancet Neurology* 12:799–810 [71]).

the SELH/Bc strain and yet more than 80% of embryos successfully complete brain formation. Hence, there appears to be no fundamental difference between humans and mice in the process of cranial neurulation.

Development of the skull and vertebral column

The skull has a dual embryonic origin. Posterior parts of the vault and base are formed by cranial mesoderm, whereas the more anterior elements have an entirely different origin from a migratory cell population: the cranial neural crest [3]. The skull vault forms directly as ‘membrane’ bone, without the intervening step of cartilage formation, whereas the skull base is first formed as a cartilaginous model that is subsequently replaced by bone. Unlike the skull, spinal vertebral structures are formed entirely from the segmented, mesodermal somites, with no contribution from the neural crest. The sclerotomal component of each somite migrates to surround the recently closed neural tube,

initially undergoing cartilaginous differentiation followed by ossification, to form the entire bony vertebra.

In both skull and vertebral column, the skeletal elements become ‘modeled’ around the already formed neural tube. Even the pattern of the skull sutures appears to be dictated by inductive interactions from the underlying dura mater [4]. Hence, if the neural tube remains open, pathologically, the skeletal elements are certain to form abnormally in consequence. This is the reason for the absent cranial vault in anencephaly and the absent dorsal vertebral elements in myelomeningocele. On the other hand, primary defects of skeletal development can also occur and, where the defect leaves an opening in the bony structure, the normally formed brain or spinal cord/meninges can herniate through, as in encephalocele or meningocele. Experimental research has been limited by a lack of models of these defects in mice; for example, there is currently no mouse model of occipital encephalocele, the most common form of congenital brain herniation seen in humans. As a result, the